Welcome to our dedicated page for Aclarion news (Ticker: ACON), a resource for investors and traders seeking the latest updates and insights on Aclarion stock.
Aclarion, Inc. (NASDAQ: ACON) is a commercial-stage healthcare technology company focused on chronic low back pain, using Magnetic Resonance Spectroscopy (MRS), biomarkers, and augmented intelligence (AI) algorithms to help physicians identify which lumbar discs may be sources of pain. This news page aggregates updates and announcements related to Aclarion’s business, technology, and clinical programs.
Readers can find coverage of Nociscan, Aclarion’s evidence-supported SaaS platform that noninvasively helps distinguish between painful and nonpainful discs in the lumbar spine. News items often highlight scan volume trends across U.S., U.K., and E.U. sites, payer coverage developments such as private insurer reimbursement in the U.K., and the addition of new imaging centers and physician users. These updates provide context on how Nociscan is being adopted in clinical practice.
A key theme in ACON news is clinical evidence generation. Articles describe the pivotal CLARITY trial, a multi-site randomized study evaluating whether incorporating Nociscan into surgical planning can improve outcomes for patients undergoing surgery for chronic low back pain. Other news discusses real-world evidence publications, including cost-effectiveness analyses and case studies published in journals like the International Journal of Spine Surgery, as well as presentations at scientific meetings such as the International Society of Pain and Neuroscience (ISPN).
Financial and corporate developments also feature prominently. Press releases cover equity financings, cash runway updates, and the company’s debt-free balance sheet, along with leadership appointments in finance and commercial roles. Together, these news items offer investors, clinicians, and other stakeholders a consolidated view of Aclarion’s progress in technology development, market expansion, and clinical validation. Users interested in ACON can monitor this page for ongoing announcements related to Nociscan, CLARITY, payer engagement, and broader corporate milestones.
Aclarion (NASDAQ:ACON) reported Q1 2026 results showing accelerating adoption of its Nociscan platform. Key metrics: scan volume +196% YoY and +64% sequential. The company holds $19.0M cash, no debt, 64 issued/pending patents, and announced a $2.5M share repurchase.
Clinical and commercial catalysts include payer reimbursements in the U.K., seven ongoing trials, and an interim CLARITY readout expected for public disclosure in late 2026. Cash runway is projected into H2 2027 on current plans.
Aclarion (Nasdaq: ACON, ACONW) appointed Daniel Keefe as Commercial Director, Western U.S., to lead regional commercial expansion and support continued adoption of Nociscan.
The hire accompanies reported triple-digit utilization growth and cites a 97% surgical success rate when all Nociscan-positive discs are treated, highlighting clinical uptake and commercial momentum.
Aclarion (Nasdaq: ACON) announced a $2.5 million stock repurchase program authorized by its board on April 22, 2026. The company expects to execute repurchases over the next 12 months, funded with existing cash and cash equivalents, subject to market conditions and legal rules.
As of March 31, 2026, Aclarion reported approximately $19.0 million in cash and cash equivalents and said the cash runway supports operations through near-term milestones, including the CLARITY randomized trial.
Aclarion (Nasdaq: ACON, ACONW) announced issuance of U.S. Patent #12,601,803 on April 16, 2026 for a machine learning–based system to analyze magnetic resonance spectroscopy (MRS) data. The patent covers AI-driven model training, automated data quality controls, and biomarker extraction within the cloud-based Nociscan platform.
The filing expands Aclarion's intellectual property to 64 issued and pending patents worldwide and is described as enabling scale, faster reports, reduced manual reviews, and more consistent outputs across imaging systems.
Aclarion (NASDAQ: ACON) received a Diamond Pinnacle Award for AI Innovation in Clinical Decision AI on April 14, 2026, recognizing its Nociscan MR spectroscopy–based SaaS platform for identifying biochemical markers of discogenic chronic low back pain.
The company cites a 97% surgical success rate when all Nociscan-positive discs are treated and notes global prevalence estimates of 266 million people with degenerative spine disease and low back pain.
Aclarion (Nasdaq: ACON) announced a commercial agreement with Weill Cornell Medicine to bring Nociscan to Weill Cornell and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center. A subset of spine patients in an IRB-approved trial (Protocol No. 22-06024915) will be eligible for Nociscan to help identify discogenic low back pain.
The study investigates dose and quantity of concentrated bone marrow aspirate (BMAC) for osteoarthritis and degenerative disc disease, with Nociscan used alongside other diagnostics.
Aclarion (Nasdaq: ACON) released a new physician video (April 7, 2026) featuring Mr. John Sutcliffe of The London Spine Clinic demonstrating real-world use of Nociscan to evaluate chronic low back pain.
Nearly 100 Nociscans have been performed at The London Clinic; Nociscan uses MR spectroscopy and proprietary signal processing to identify chemical biomarkers linked to disc pain. According to the company, clinical data showed up to 97% surgical success when all Nociscan-positive discs are treated, and the video signals growing physician adoption at a leading international center.
Summary not available.
Aclarion (Nasdaq: ACON, ACONW) announced that its Board adopted a limited duration stockholder rights plan effective March 19, 2026 that expires in one year. The Rights Plan is intended to help stockholders realize long-term value and to reduce the likelihood of control changes without an appropriate premium.
The plan applies equally to all current and future stockholders, was adopted unanimously by the Board, and was not adopted in response to any specific acquisition proposal.
Aclarion (Nasdaq: ACON, ACONW) published a CEO shareholder letter outlining 2026 priorities: expand adoption of the Nociscan platform, pursue reimbursement with U.S. regional insurers, grow clinical evidence, and advance commercial engagement with physicians and imaging centers.
The company highlighted an initial CLARITY trial readout in Q4 2026 and a strong balance sheet with cash runway into 2028 to support execution of these catalysts.